Interferon α 2B for treatment of complex cutaneous haemangiomas of infancy

Enrico Rampini, Corrado Occella, Paolo Rampini, Dario Bleidl

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Summary: Interferon alpha 2b for the treatment of complex haemangiomas of infancy (HI) and childhood. Background: Recombinant interferon α has been used with success in the treatment of complex haemangiomas of infancy. Materials and methods: Eleven infants and children (10 females and 1 male) with complex haemangiomas (age 3-14 months) were treated with interferon α 2b by subcutaneous infection of up to 1 million UI/m2/day three times a week for 2 weeks; then the dosage was increased to 3 million UI/m2/day three times a week. The duration of treatment ranged from 6 to 14 months. A decrease of 50% or more in the dimension of haemangiomas that was maintained for at least 6 months during the treatment or after the withdrawal of the medication was considered a consequence of therapy. Results: In 1 case regression of HI was of 20%; in the other 10 cases, regression ranged from 60% to 90%. The side effects of interferon therapy were mild and transient. Our treatment schedule shows that the administration of interferon α 2b three times a week is as effective as the daily administration of the drug. In our opinion interferon α 2b is a safe agent in the treatment of complex haemangiomas of infancy and therefore should be considered a first line therapeutic option.

Original languageEnglish
Pages (from-to)123-128
Number of pages6
JournalJournal of the European Academy of Dermatology and Venereology
Volume9
Issue number2
DOIs
Publication statusPublished - 1997

Fingerprint

Hemangioma
Interferons
Skin
Therapeutics
interferon alfa-2b
Appointments and Schedules
Infection
Pharmaceutical Preparations

Keywords

  • Intefferon α 2b
  • Problematic haemangiomas

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

Interferon α 2B for treatment of complex cutaneous haemangiomas of infancy. / Rampini, Enrico; Occella, Corrado; Rampini, Paolo; Bleidl, Dario.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 9, No. 2, 1997, p. 123-128.

Research output: Contribution to journalArticle

@article{829340d8a2e242f8afd2ee24cd294c5b,
title = "Interferon α 2B for treatment of complex cutaneous haemangiomas of infancy",
abstract = "Summary: Interferon alpha 2b for the treatment of complex haemangiomas of infancy (HI) and childhood. Background: Recombinant interferon α has been used with success in the treatment of complex haemangiomas of infancy. Materials and methods: Eleven infants and children (10 females and 1 male) with complex haemangiomas (age 3-14 months) were treated with interferon α 2b by subcutaneous infection of up to 1 million UI/m2/day three times a week for 2 weeks; then the dosage was increased to 3 million UI/m2/day three times a week. The duration of treatment ranged from 6 to 14 months. A decrease of 50{\%} or more in the dimension of haemangiomas that was maintained for at least 6 months during the treatment or after the withdrawal of the medication was considered a consequence of therapy. Results: In 1 case regression of HI was of 20{\%}; in the other 10 cases, regression ranged from 60{\%} to 90{\%}. The side effects of interferon therapy were mild and transient. Our treatment schedule shows that the administration of interferon α 2b three times a week is as effective as the daily administration of the drug. In our opinion interferon α 2b is a safe agent in the treatment of complex haemangiomas of infancy and therefore should be considered a first line therapeutic option.",
keywords = "Intefferon α 2b, Problematic haemangiomas",
author = "Enrico Rampini and Corrado Occella and Paolo Rampini and Dario Bleidl",
year = "1997",
doi = "10.1016/S0926-9959(97)00071-8",
language = "English",
volume = "9",
pages = "123--128",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "wiley",
number = "2",

}

TY - JOUR

T1 - Interferon α 2B for treatment of complex cutaneous haemangiomas of infancy

AU - Rampini, Enrico

AU - Occella, Corrado

AU - Rampini, Paolo

AU - Bleidl, Dario

PY - 1997

Y1 - 1997

N2 - Summary: Interferon alpha 2b for the treatment of complex haemangiomas of infancy (HI) and childhood. Background: Recombinant interferon α has been used with success in the treatment of complex haemangiomas of infancy. Materials and methods: Eleven infants and children (10 females and 1 male) with complex haemangiomas (age 3-14 months) were treated with interferon α 2b by subcutaneous infection of up to 1 million UI/m2/day three times a week for 2 weeks; then the dosage was increased to 3 million UI/m2/day three times a week. The duration of treatment ranged from 6 to 14 months. A decrease of 50% or more in the dimension of haemangiomas that was maintained for at least 6 months during the treatment or after the withdrawal of the medication was considered a consequence of therapy. Results: In 1 case regression of HI was of 20%; in the other 10 cases, regression ranged from 60% to 90%. The side effects of interferon therapy were mild and transient. Our treatment schedule shows that the administration of interferon α 2b three times a week is as effective as the daily administration of the drug. In our opinion interferon α 2b is a safe agent in the treatment of complex haemangiomas of infancy and therefore should be considered a first line therapeutic option.

AB - Summary: Interferon alpha 2b for the treatment of complex haemangiomas of infancy (HI) and childhood. Background: Recombinant interferon α has been used with success in the treatment of complex haemangiomas of infancy. Materials and methods: Eleven infants and children (10 females and 1 male) with complex haemangiomas (age 3-14 months) were treated with interferon α 2b by subcutaneous infection of up to 1 million UI/m2/day three times a week for 2 weeks; then the dosage was increased to 3 million UI/m2/day three times a week. The duration of treatment ranged from 6 to 14 months. A decrease of 50% or more in the dimension of haemangiomas that was maintained for at least 6 months during the treatment or after the withdrawal of the medication was considered a consequence of therapy. Results: In 1 case regression of HI was of 20%; in the other 10 cases, regression ranged from 60% to 90%. The side effects of interferon therapy were mild and transient. Our treatment schedule shows that the administration of interferon α 2b three times a week is as effective as the daily administration of the drug. In our opinion interferon α 2b is a safe agent in the treatment of complex haemangiomas of infancy and therefore should be considered a first line therapeutic option.

KW - Intefferon α 2b

KW - Problematic haemangiomas

UR - http://www.scopus.com/inward/record.url?scp=0030757745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030757745&partnerID=8YFLogxK

U2 - 10.1016/S0926-9959(97)00071-8

DO - 10.1016/S0926-9959(97)00071-8

M3 - Article

VL - 9

SP - 123

EP - 128

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 2

ER -